Skip to Content

Satsuma Pharmaceuticals, Inc.

Merger

  • Date:
  • 4/17/2023
  • Company Name:
  • Satsuma Pharmaceuticals, Inc.
  • Stock Symbol:
  • STSA
  • Company Name - Buyer:
  • Shin Nippon Biomedical Laboratories, Ltd.
  • Stock Symbol - Buyer:
  • 2395
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 4/16/2023

Case Finder

Locate any case using the tools below.

NEW YORK, April 17, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) (“Satsuma”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Shin Nippon Biomedical Laboratories, Ltd. (TSE: 2395) (“SNBL”).

On April 16, 2023, Satsuma announced that it had entered into an agreement to be acquired by SNBL in a cash and CVR deal. Pursuant to the merger agreement, SNBL will acquire Satsuma for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right (“CVR”) of up to $5.77 per share.

Bragar Eagel & Squire is concerned that Satsuma’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Satsuma’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Satsuma Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: